Literature DB >> 24563734

Mechanisms of mixed-lineage leukemia.

Andrew G Muntean1.   

Abstract

Advances in our understanding of the genetic determinants of leukemia have translated to better treatment options and improved survival of patients with acute myeloid and acute lymphoid leukemia. However, some leukemias, such as those bearing 11q23 (MLL) translocations, result in aggressive diseases with a relatively poor prognosis, despite improved treatments such as allogeneic hematopoietic stem cell transplantation. This article will briefly review the functions and regulation of wild-type MLL during normal hematopoiesis, while focusing on recent advances in our understanding of the molecular mechanisms governing MLL leukemias. The transcriptional targets, cooperating signaling pathways and molecular machinery involved in MLL-associated leukemias will be discussed, as well as how these may be harnessed for more personalized treatment of this disease.

Entities:  

Year:  2013        PMID: 24563734      PMCID: PMC3927937          DOI: 10.2217/ijh.13.20

Source DB:  PubMed          Journal:  Int J Hematol Oncol        ISSN: 2045-1393


  121 in total

1.  Binding of the MLL PHD3 finger to histone H3K4me3 is required for MLL-dependent gene transcription.

Authors:  Pei-Yun Chang; Robert A Hom; Catherine A Musselman; Li Zhu; Alex Kuo; Or Gozani; Tatiana G Kutateladze; Michael L Cleary
Journal:  J Mol Biol       Date:  2010-05-07       Impact factor: 5.469

Review 2.  Flavopiridol, the first cyclin-dependent kinase inhibitor: recent advances in combination chemotherapy.

Authors:  L M Wang; D M Ren
Journal:  Mini Rev Med Chem       Date:  2010-10       Impact factor: 3.862

3.  Activated K-Ras protein accelerates human MLL/AF4-induced leukemo-lymphomogenicity in a transgenic mouse model.

Authors:  H Tamai; K Miyake; M Takatori; N Miyake; H Yamaguchi; K Dan; T Shimada; K Inokuchi
Journal:  Leukemia       Date:  2011-02-11       Impact factor: 11.528

4.  Inhibition of Rac GTPase signaling and downstream prosurvival Bcl-2 proteins as combination targeted therapy in MLL-AF9 leukemia.

Authors:  Benjamin Mizukawa; Junping Wei; Mahesh Shrestha; Mark Wunderlich; Fu-Sheng Chou; Andrea Griesinger; Chad E Harris; Ashish R Kumar; Yi Zheng; David A Williams; James C Mulloy
Journal:  Blood       Date:  2011-09-22       Impact factor: 22.113

5.  Clinical features, cytogenetics and outcome in acute lymphoblastic and myeloid leukaemia of infancy: report from the MRC Childhood Leukaemia working party.

Authors:  J M Chessells; C J Harrison; H Kempski; D K H Webb; K Wheatley; I M Hann; R F Stevens; G Harrison; B E Gibson
Journal:  Leukemia       Date:  2002-05       Impact factor: 11.528

6.  MLL-AF9 and MLL-ENL alter the dynamic association of transcriptional regulators with genes critical for leukemia.

Authors:  Sara C Monroe; Stephanie Y Jo; Daniel S Sanders; Venkatesha Basrur; Kojo S Elenitoba-Johnson; Robert K Slany; Jay L Hess
Journal:  Exp Hematol       Date:  2010-09-18       Impact factor: 3.084

7.  Genetic and pharmacologic inhibition of β-catenin targets imatinib-resistant leukemia stem cells in CML.

Authors:  Florian H Heidel; Lars Bullinger; Zhaohui Feng; Zhu Wang; Tobias A Neff; Lauren Stein; Demetrios Kalaitzidis; Steven W Lane; Scott A Armstrong
Journal:  Cell Stem Cell       Date:  2012-04-06       Impact factor: 24.633

8.  Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9.

Authors:  Andrei V Krivtsov; David Twomey; Zhaohui Feng; Matthew C Stubbs; Yingzi Wang; Joerg Faber; Jason E Levine; Jing Wang; William C Hahn; D Gary Gilliland; Todd R Golub; Scott A Armstrong
Journal:  Nature       Date:  2006-07-16       Impact factor: 49.962

9.  Hierarchical maintenance of MLL myeloid leukemia stem cells employs a transcriptional program shared with embryonic rather than adult stem cells.

Authors:  Tim C P Somervaille; Christina J Matheny; Gary J Spencer; Masayuki Iwasaki; John L Rinn; Daniela M Witten; Howard Y Chang; Sheila A Shurtleff; James R Downing; Michael L Cleary
Journal:  Cell Stem Cell       Date:  2009-02-06       Impact factor: 24.633

10.  Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia.

Authors:  Mark A Dawson; Rab K Prinjha; Antje Dittmann; George Giotopoulos; Marcus Bantscheff; Wai-In Chan; Samuel C Robson; Chun-wa Chung; Carsten Hopf; Mikhail M Savitski; Carola Huthmacher; Emma Gudgin; Dave Lugo; Soren Beinke; Trevor D Chapman; Emma J Roberts; Peter E Soden; Kurt R Auger; Olivier Mirguet; Konstanze Doehner; Ruud Delwel; Alan K Burnett; Phillip Jeffrey; Gerard Drewes; Kevin Lee; Brian J P Huntly; Tony Kouzarides
Journal:  Nature       Date:  2011-10-02       Impact factor: 49.962

View more
  6 in total

Review 1.  Epigenetic roots of immunologic disease and new methods for examining chromatin regulatory pathways.

Authors:  Ian A MacDonald; Nathaniel A Hathaway
Journal:  Immunol Cell Biol       Date:  2014-12-23       Impact factor: 5.126

2.  Acute myeloid leukemia with t(10;11): a pathological entity with distinct clinical presentation.

Authors:  Courtney D DiNardo; Guilin Tang; Naveen Pemmaraju; Sa A Wang; Allison Pike; Guillermo Garcia-Manero; Jorge Cortes; Carlos Bueso-Ramos; Hagop M Kantarjian
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2014-06-21

3.  A novel de novo mutation (p.Pro1310Glnfs*46) in KMT2A caused Wiedemann-Steiner Syndrome in a Chinese boy with postnatal growth retardation: a case report.

Authors:  Minghui Chen; Ruihong Liu; Chao Wu; Xunhua Li; Yiming Wang
Journal:  Mol Biol Rep       Date:  2019-06-27       Impact factor: 2.316

Review 4.  Interstitial Deletions Generating Fusion Genes.

Authors:  Ioannis Panagopoulos; Sverre Heim
Journal:  Cancer Genomics Proteomics       Date:  2021 May-Jun       Impact factor: 4.069

5.  Rare MLL-ELL fusion transcripts in childhood acute myeloid leukemia-association with young age and myeloid sarcomas?

Authors:  Ioannis Panagopoulos; Ludmila Gorunova; Gitte Kerndrup; Signe Spetalen; Anne Tierens; Liv T N Osnes; Kristin Andersen; Lil-Sofie Ording Müller; Marit Hellebostad; Bernward Zeller; Sverre Heim
Journal:  Exp Hematol Oncol       Date:  2016-03-05

6.  Pathways, Processes, and Candidate Drugs Associated with a Hoxa Cluster-Dependency Model of Leukemia.

Authors:  Laura M Kettyle; Charles-Étienne Lebert-Ghali; Ivan V Grishagin; Glenda J Dickson; Paul G O'Reilly; David A Simpson; Janet J Bijl; Ken I Mills; Guy Sauvageau; Alexander Thompson
Journal:  Cancers (Basel)       Date:  2019-12-17       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.